GlassScriptPhysician profile
Saad Sanyurah
NPI 1639157852
$3,522.94
in general payments reported to CMS, 2019-2025
21 companies · $51.82 in 2025
The $51.82 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $648 · 2021: $677 · 2022: $541 · 2023: $755 · 2024: $237 · 2025: $51.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946 · Education: $98.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.81 |
| Education | $98.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $901.74 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $694.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $303.96 | 2019-2023 | Dupixent |
| Genzyme Corporation | $289.10 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $202.96 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $186.49 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $171.38 | 2020-2023 | |
| Genentech USA, INC. | $168.34 | 2019-2024 | Xolair |
| Optinose US, INC. | $131.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.96 | 2019-2022 | |
| Amgen INC. | $90.72 | 2022-2024 | Tezspire |
| Sanofi-Aventis U.S. LLC | $61.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.08 | 2021-2023 | Cuvitru |
| Biocryst US Sales Co., LLC | $43.26 | 2022-2024 | Orladeyo |
| Pfizer INC. | $28.56 | 2020-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $27.04 | 2021-2022 | |
| Blueprint Medicines Corporation | $18.74 | 2023 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $18.48 | 2025 | Neffy |
| Horizon Therapeutics Plc | $17.24 | 2020 | |
| Kaleo, INC. | $15.20 | 2021 | |
| Alk-Abello, INC | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Sanyurah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.